Fulgent Genetics (NASDAQ:FLGT) Releases FY24 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY24 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $0.33 for the period, compared to the consensus estimate of ($0.39). Fulgent Genetics also updated its FY 2024 guidance to 0.330-0.330 EPS.

Fulgent Genetics Trading Down 2.9 %

NASDAQ:FLGT opened at $22.02 on Friday. Fulgent Genetics has a 1 year low of $18.76 and a 1 year high of $30.68. The stock has a market cap of $667.21 million, a price-to-earnings ratio of -4.02 and a beta of 1.51. The stock has a 50-day moving average price of $21.08 and a two-hundred day moving average price of $21.44.

Insider Buying and Selling at Fulgent Genetics

In other news, CEO Ming Hsieh sold 2,313 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total transaction of $52,805.79. Following the completion of the transaction, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at $16,147,088.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders sold 4,324 shares of company stock valued at $98,717. Company insiders own 32.66% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.